Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A0HGQF5
Thu, 30.06.2022
MagForce AG
MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights
MagForce USA received approval by the Centers for Medicare and Medicaid Services (CMS) to cover the majority of treatment-related costs in the ongoing clinical trial in the US after commercial payment code approval from the American Medical Association (AM [ … ]
Thu, 30.06.2022
MagForce AG
MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights
MagForce USA received approval by the Centers for Medicare and Medicaid Services (CMS) to cover the majority of treatment-related costs in the ongoing clinical trial in the US after commercial payment code approval from the American Medical Association (AM [ … ]
Fri, 08.04.2022
MagForce AG
MagForce AG: MagForce USA, Inc. receives Payment Code Approval by the American Medical Association for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Category III CPT codes will ensure seamless billing and tracking process for payers already at the time FDA marketing approval is secured
NanoTherm Therapy CPT codes will [ … ]
Mon, 20.12.2021
MagForce AG
MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval
Stage 2b of the single arm study will enroll up to 100 men who have progressed to intermediate risk prostate cancer stage and are under active surveillance
First p [ … ]
Fri, 05.11.2021
MagForce AG
MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Following FDA green-light, Stage 2b of the pivotal trial will begin immediately
Patient screening and enrollment will be expedited and, [ … ]
Thu, 28.10.2021
MagForce AG
MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights
- Europe: Significant upward trend - both in patient numbers and in the number of centers in Europe offering NanoTherm therapy
- USA: Stage 2a of pivotal single-arm study for the focal ablation of intermediate risk prostate cancer successfully completed - Stage 2b with f [ … ]
Wed, 13.10.2021
MagForce AG
MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Berlin, Germany and Nevada, USA, October 13, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company i [ … ]
Thu, 30.09.2021
MagForce AG
MagForce AG and CHIP Hospital Málaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain
- Complejo Hospitalario Integral Privado (CHIP) will be first clinic in Spain to offer MagForce's technology for the commercial treatment of brain cancer patients
- Additio [ … ]
Thu, 12.08.2021
MagForce AG
MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board
Berlin, Germany, and Nevada, USA, August 12, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the results of the 2021 Annual Gener [ … ]
Wed, 30.06.2021
MagForce AG
MagForce AG Publishes Financial Results for the Year 2020 and Operative Highlights
- Europe: High growth in treatment numbers beginning of 2020 - after severe COVID-19 impact European roll-out now picks up speed again
- USA: Stage 2a of pivotal single-arm study for the focal ablation of intermediate risk prostate cancer completed - additional dat [ … ]